View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Bruno Cavalier ... (+3)
  • Bruno Cavalier
  • Oliver Metzger
  • Sinan Doganli
Bruno Cavalier ... (+3)
  • Bruno Cavalier
  • Oliver Metzger
  • Sinan Doganli
CON CONTINENTAL AKTIENGESELLSCHAFT
NDX1 NORDEX SE
FME FRESENIUS MEDICAL CARE AG
FRA FRAPORT AG
TKA THYSSENKRUPP AG
WCH WACKER CHEMIE AG
G1A GEA GROUP AG
MC LVMH MOET HENNESSY LOUIS VUITTON SE
MTX MTU AERO ENGINES AG
CBK COMMERZBANK AG
HO THALES SA
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
EVT EVOTEC SE
HNR1 HANNOVER RUECK SE
GBF BILFINGER SE
AFX CARL ZEISS MEDITEC AG
SRT3 SARTORIUS AG PREF
GLJ GRENKE AG
UTDI UNITED INTERNET AG
LXS LANXESS AG
GXI GERRESHEIMER AG
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
VNA VONOVIA SE
ELG ELMOS SEMICONDUCTOR SE
BOSS HUGO BOSS AG
SDF K+S AG
ZAL ZALANDO SE
BAS BASF SE
FRE FRESENIUS SE & CO. KGAA
BAYN BAYER AG
HEN3 HENKEL AG & CO. KGAA PREF
01913 PRADA S.P.A.
IMPN IMPLENIA AG
DEZ DEUTZ AG
INH INDUS HOLDING AG
AIXA AIXTRON SE
KRN KRONES AG
WIE WIENERBERGER AG
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
BC8 BECHTLE AG
ADN1 ADESSO AG
EVK EVONIK INDUSTRIES AG
KGX KION GROUP AG
MONC MONCLER SPA
WAF SILTRONIC AG
SMHN SUESS MICROTEC AG
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
NN NN GROUP N.V.
HBH HORNBACH HOLDING AG & CO. KGAA
FNTN FREENET AG
JUN3 JUNGHEINRICH AG PREF
BFSA BEFESA SA
JST JOST WERKE AG
DMP DERMAPHARM HOLDING SE
VOS VOSSLOH AG
SANT S&T AG
JEN JENOPTIK AG
AEIN ALLGEIER HOLDING AG
KBX KNORR-BREMSE AG
HAG HENSOLDT AG
SFQ SAF-HOLLAND SE
NA9 NAGARRO
FPE3 FUCHS PETROLUB SE
SPAC 468 SPAC I SE
STM STABILUS SE
IOS IONOS GROUP SE
TUI TUI AG
SCHOTT PHARMA AG
CVC CVC CAPITAL PARTNERS PLC
Bruno Cavalier ... (+3)
  • Bruno Cavalier
  • Oliver Metzger
  • Sinan Doganli
Bruno Cavalier ... (+3)
  • Bruno Cavalier
  • Oliver Metzger
  • Sinan Doganli
CON CONTINENTAL AKTIENGESELLSCHAFT
NDX1 NORDEX SE
FME FRESENIUS MEDICAL CARE AG
FRA FRAPORT AG
TKA THYSSENKRUPP AG
WCH WACKER CHEMIE AG
G1A GEA GROUP AG
MC LVMH MOET HENNESSY LOUIS VUITTON SE
MTX MTU AERO ENGINES AG
CBK COMMERZBANK AG
HO THALES SA
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
EVT EVOTEC SE
HNR1 HANNOVER RUECK SE
GBF BILFINGER SE
AFX CARL ZEISS MEDITEC AG
SRT3 SARTORIUS AG PREF
GLJ GRENKE AG
UTDI UNITED INTERNET AG
LXS LANXESS AG
GXI GERRESHEIMER AG
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
VNA VONOVIA SE
ELG ELMOS SEMICONDUCTOR SE
BOSS HUGO BOSS AG
SDF K+S AG
ZAL ZALANDO SE
BAS BASF SE
FRE FRESENIUS SE & CO. KGAA
BAYN BAYER AG
HEN3 HENKEL AG & CO. KGAA PREF
01913 PRADA S.P.A.
IMPN IMPLENIA AG
DEZ DEUTZ AG
INH INDUS HOLDING AG
AIXA AIXTRON SE
KRN KRONES AG
WIE WIENERBERGER AG
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
BC8 BECHTLE AG
ADN1 ADESSO AG
EVK EVONIK INDUSTRIES AG
KGX KION GROUP AG
MONC MONCLER SPA
WAF SILTRONIC AG
SMHN SUESS MICROTEC AG
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
NN NN GROUP N.V.
HBH HORNBACH HOLDING AG & CO. KGAA
FNTN FREENET AG
JUN3 JUNGHEINRICH AG PREF
BFSA BEFESA SA
JST JOST WERKE AG
DMP DERMAPHARM HOLDING SE
VOS VOSSLOH AG
SANT S&T AG
JEN JENOPTIK AG
AEIN ALLGEIER HOLDING AG
KBX KNORR-BREMSE AG
HAG HENSOLDT AG
SFQ SAF-HOLLAND SE
NA9 NAGARRO
FPE3 FUCHS PETROLUB SE
SPAC 468 SPAC I SE
STM STABILUS SE
IOS IONOS GROUP SE
TUI TUI AG
SCHOTT PHARMA AG
CVC CVC CAPITAL PARTNERS PLC
Oliver Metzger ... (+2)
  • Oliver Metzger
  • Sinan Doganli

ODDO : Final Feedback. The German paradox: Strong index performance, b...

While the DAX year-to-date has clearly outperformed most of the large European and US indexes (except the IBEX), many corporates presenting at the 16th edition of our Corporate Conference, hosted jointly by ODDO BHF and Commerzbank, were still focused on the macroeconomic environment, geopolitical tensions and tariffs and the related impact on their sectors. Unsurprisingly, the clearly most positive sector was defence. For others, the picture was more mixed inside the sectors. Based on the feedb...

Oliver Metzger ... (+2)
  • Oliver Metzger
  • Sinan Doganli

ODDO : Feedback Day 1

ODDO BHF and Commerzbank are jointly hosting the 16th edition of the Corporate Conference on 3 and 4 of September 2025 in Frankfurt am Main. This year, we are welcoming 88 German small, mid and large cap companies. Among the companies which presented during the first day, we highlight, notably, positive feedback from Adesso, BASF, Befesa, Commerzbank, Fresenius Medical Care, Fresenius SE, Fuchs, Hannover RE, Hensoldt, Implenia, Sartorius, Schott Pharma, Tonies and Zalando ADESSO (+) - Positive ...

Evotec SE: 1 director

A director at Evotec SE bought 50,000 shares at 5.918EUR and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Thomas J. Schiessle
  • Thomas J. Schiessle

Weak economy delays "Profitability Restart" - 25 guidance correction -...

The Q2/25 KPIs show a deterioration in revenue and EBITDA margins - contrary to management and market expectations (revenue -6% YoY to €171.2m / margin: -4.08%; EPS €-0.25), but these are exaggerated due to phasing effects and reset savings. Revenue and margins in the "restart phase" starting Q3/25 are expected to expand. However, the necessary revival of customer demand in the pharma and biotech industry is still lacking (contractionary US R&D and industrial policy, hesitant investments). There...

Thomas J. Schiessle
  • Thomas J. Schiessle

Schwache Konjunktur verzögert „Profitability Restart“ - 25er Guidance-...

Die Q2/25-KPIs zeigen - entgegen der Management- und Markt-Erwartung - eine Umsatz- und EBITDA Margen-Verschlechterung (Umsatz -6% YoY auf € 171,2 Mio./Marge: -4,08 %; EPS € -0,25), doch sind diese durch Phasing-Effekte und Reset-Einsparungen überzeichnet. Umsatz und Margen in der „Restart-Phase“ ab Q3/25 sollen ausgeweitet werden. Doch die dafür nötige wiederauflebende Kundennachfrage in Pharma- und Biotech-Industrie bleibt bis heute aus (kontraktive US-R&D- und Industriepolitik, zögerliche Inv...

Oliver Metzger ... (+2)
  • Oliver Metzger
  • Stephan Wulf
Damien Choplain ... (+3)
  • Damien Choplain
  • Maria Vara
  • Oscar Haffen Lamm

End of coverage

From 5th August 2025, we will no longer include the following companies in our coverage:EVOTECMEDIOSDBV Technologies

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Evotec - Another Warning – PT Cut to €5.40 (SELL, TP EUR5.40 [7], 9pgs...

Following yesterday's cut to sales guidance, we cut our PT to €5.40 and L-T revenues by 10-15%. We are 40% below consensus EBITDA in 2028 despite including significantly more cost savings. We show the base business is loss making this year & could just break even in 2026. We are most concerned about the reliance on single lumpy contracts. The SDZ milestones will mostly disappear by 2028 & the commercial revenues required to offset them imply biosimilar sales of €550m by 2030 for drugs that will ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch